Mustafa Özdoğan, MD· @ozdogan_md · X·· 1 天前评分70
正文 · 原文
KRAScendo 1: the first head-to-head comparison in KRAS G12C-targeted therapy, presented at ESMO and published in NEJM.
Does this change second-line standard of care?
#ESMO26 #Oncology #LungCancer
107 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org来源：Mustafa Özdoğan, MD · x.com